Related Experiment Videos
Chagas' heart disease
1Section of Cardiology, Anis Rassi Hospital, Goiânia, Goias, Brazil.
Insights
Chagas' disease, caused by Trypanosoma cruzi, affects millions in Latin America. Early diagnosis and treatment with benznidazole, alongside cardiac management, are crucial for improving patient outcomes and preventing transmission.
Area of Science:
- Infectious Diseases
- Cardiology
- Parasitology
Background:
- Chagas' disease is a significant public health concern in Latin America, caused by the protozoan parasite Trypanosoma cruzi.
- Transmission occurs via infected insect vectors or nonvectorial routes like blood transfusions.
- Chronic infection often leads to severe cardiac complications decades after initial exposure.
Purpose of the Study:
- To review the epidemiology, diagnosis, and management of Chagas' disease, with a focus on cardiac involvement.
- To highlight the challenges posed by migration and potential transmission in non-endemic regions.
- To discuss current and potential therapeutic strategies for Chagas' heart disease.
Main Methods:
- Review of existing literature on Chagas' disease epidemiology, clinical presentation, and treatment.
- Analysis of diagnostic criteria, including serologic tests and clinical manifestations.
- Evaluation of therapeutic options for both acute and chronic phases of the infection.
Main Results:
- Chagas' heart disease can manifest as arrhythmias, heart failure, and sudden death.
- An estimated 16–18 million individuals are infected in Latin America.
- Misdiagnosis in immigrant populations and transfusion-related transmission are critical concerns.
Conclusions:
- Early diagnosis and treatment with benznidazole are effective for initial infections and may benefit chronic cases.
- Management of cardiac involvement using medications like amiodarone, ACE inhibitors, and pacemakers can improve survival.
- Increased awareness and diagnostic efforts are essential to address Chagas' disease in non-endemic countries.
Abstract:
Chagas' disease is caused by a protozoan parasite, Trypanosoma cruzi, that is transmitted to humans through the feces of infected bloodsucking insects in endemic areas of Latin America, or occasionally by nonvectorial mechanisms, such as blood transfusion. Cardiac involvement, which typically appears decades after the initial infection, may result in cardiac arrhythmias, ventricular aneurysm, congestive heart failure, thromboembolism, and sudden cardiac death. Between 16 and 18 million persons are infected in Latin America. The migration of infected Latin Americans to the United States or other countries where the disease is uncommon poses two problems: the misdiagnosis or undiagnosis of Chagas' heart disease in these immigrants and the possibility of transmission of Chagas' disease through blood transfusions. Diagnosis is based on positive serologic tests and the clinical features. The antiparasitic drug, benznidazole, is effective when given for the initial infection and may also be beneficial for the chronic phase. The use of amiodarone, angiotensin-converting enzyme inhibitors, and pacemaker implantation may contribute to a better survival in selected patients with cardiac involvement of chronic Chagas' disease.